Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > Night-shift work and breast cancer risk: potential biological mechanism identified
  • News

Night-shift work and breast cancer risk: potential biological mechanism identified

  • 6 July 2020
  • Adriana Albini
Night-shift work and breast cancer risk: potential biological mechanism identified
Total
0
Shares
0
0
0
0
0

Is night-shift work a risk factor for breast cancer? Experimental research just published in Nature Communications gives the molecular basis for asserting that it may well be.

Researchers at Paris-Saclay University, with colleagues from Inserm and Inrae, studied the association between night work and increased tumour aggressiveness. They created a simulated jet-lag situation for mice that reproduced a change in the rhythm between day and night. The collaborative teams observed how disturbances in the circadian rhythm had an impact on breast cancer stem cells and the development of breast tumours. In particular they detected an increased spread of cancer cells and the formation of metastases. They speculated that this is related to increased inflammation. The higher expression of chemokines in circadian-disturbed mice induced infiltration of pro-inflammatory myeloid cells in the microenvironment, causing suppression of adaptive immunity.

Several mechanisms have been postulated before to explain an association between night work and breast cancer, with inhibition of the hormone melatonin by the use of artificial light at night widely seen as the most likely (eg Hansen J, Curr Environ Health Rep 2017).
In the study published in Nature Communications, the use of a chemokine receptor inhibitory drug, which influences the neutrophils and myeloid cells, limited the effect on tumour progression, confirming a role for inflammation.

The topic is controversial. In June 2019, a working group convened by the International Agency for Research on Cancer (IARC) concluded that “night shift work” is “probably carcinogenic to humans” (a Group 2A carcinogen). A paper by the Department of Hygiene and Epidemiology of the Medical University of Łódź, Poland, published the following January (Int J Environ Res Public Health, 2020), found a significantly higher risk of cancer among people working at night. However, other studies have found little or no correlation at all. Exactly a year ago (7 July 2020) Lancet Oncology reported a new cohort study concluding that night shift work does not increase the risk of breast cancer.

The evidence from the Nature Communications study provides important additional evidence to support the proposition that such a link does exist, and about the molecular mechanism involved.

Risk factors for breast cancer are multiple: hereditary (mostly BRCA1 and 2 genes), behavioural (smoke, pollution, parity, lactation) or related to poor nutrition or alcohol consumption. Hormonal factors play an obvious role. There is still a long way to go to understand the influence of time-shifts and work-related stress.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • breast cancer
  • circadian rhythms
  • risk factors
  • shift work
Adriana Albini

Adriana Albini is scientific collaborator at the European Institute of Oncology (IEO) in Milan, Professor of General Pathology at the Milan Bicocca University, she has been deputy Chief of Genoa Cancer Center and Head of Research Department of Reggio Emilia Cancer Center and Scientific Director of MultiMedica Onlus.

Previous Article
  • Articles
  • Featured

Guiding career paths from trainee doctor to oncology leader

  • 6 July 2020
  • Anna Wagstaff
View Post
Next Article
  • In the Hot Seat

Solange Peters: ESMO President

  • 6 July 2020
  • Editorial Staff
View Post
You May Also Like
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Yeva Margaryan
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Yeva Margaryan
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Yeva Margaryan
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
View Post
  • News

Low-dose aspirin reduces colorectal cancer recurrence in patients with PI3K alterations

  • Janet Fricker
  • 6 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
  • Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
    • 21 March 2025
Article
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • Istanbul, Ankara take action on HPV vaccination, as government delays promised national programme
    • 1 April 2025
  • Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
    • 31 March 2025
Social

Would you follow us ?

Contents
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • “I really care about people.” – Philip Kantoff, A Life in Science and Medicine
    • 5 May 2025
  • What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader
    • 23 April 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.